Precision Takes Shape
Easily customize therapy to match each patient’s needs with the Vercise Genus™ DBS system. Featuring an MR-conditional portfolio and miniaturized components, Vercise Genus delivers the next level of precision in directional stimulation, without compromise.
Unprecedented Options for Customization
Boston Scientific DBS systems offer the flexibility you need to treat every patient’s need today and flexibility for the future. Our Genus portfolio features directional and non-directional lead options, and thin, contoured rechargeable and non-rechargeable MR conditional IPGs:
Our Most Advanced Technology:
The Vercise Genus DBS System
Shape outcomes like never before, today and tomorrow. With Cartesia 3D, precisely shape and steer stimulation where it’s needed most and leverage more programming flexibility to help manage a patient’s ever evolving needs.
Precision Made Personal
Choose between rechargeable and non-rechargeable full-body MR conditional**, wireless Bluetooth® IPGs powered by Cartesia 3D.
Precision in Hand
Vercise™ Neural Navigator 4 offers a streamlined approach to personalized DBS programming. The platform features secure, wireless Bluetooth® communication, intuitive directional steering controls, visualization of stimulation field modeling and insightful clinical effect annotations.
Stay Up to Date
Learn more about our DBS product news and the latest clinical data.
An ImageReady™MR Conditional Portfolio
Learn how the ImageReady MR Conditional DBS System allows patients to safely undergo MRI scans.
Find procedural coding and reimbursement information for inpatient, outpatient, office and ASC codes.
Get customer support
Other Boston Scientific DBS Systems
The rechargeable DBS system is powered by Multiple Independent Control and is compatible with the Vercise Cartesia™ directional lead with full-body MRI access**.
The Vercise PC DBS System combines a non-rechargeable IPG, MICC and directionality in a thin, contoured low-profile IPG designed for patient comfort.
Vercise DBS is engineered for precise neural targeting to customize therapy for patients with Parkinson’s disease.